This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Broadcom, Optimer: After-Hours Trading

NEW YORK (TheStreet) -- Broadcom (BRCM) shares pulled back in late trades on Friday after the stock saw a healthy gain in the regular session following bullish comments from FBR Capital Markets.

FBR added Broadcom to its top picks list, saying the company is positioned to benefit from strong wireless baseband demand, and the stock rose 5.4% to $36.52 on Friday with volume reaching 23.4 million, more than twice the trailing three-month daily average churn of 9.7 million.



Even with that gain, the shares are still down about 20% so far in 2011, and the stock was last quoted in after-hours action at $34.65, down 5.1%, on volume of around 120,000, according to Nasdaq.com.

Most of Wall Street is bullish on Broadcom with 26 of the 42 analysts covering the stock at strong buy (12) or buy (14), and the median 12-month price target sitting at $45, implying potential upside of 22% from here.

Broadcom shares were trading above $40 before the company's fiscal first-quarter report on April 26. Broadcom beat the average analysts' view for the March-ended quarter but gave a weak guidance.

Optimer Pharmaceuticals

Shares of Optimer Pharmaceuticals (OPTR) rose after Friday's closing bell as the company received approval from the Food and Drug Administration of its Dificid anti-bacterial drug for the treatment of clostridium difficile-associated diarrhea in adults 18 years of age and older.

""The incidence and severity of CDAD has increased dramatically in the U.S. in the past decade and is continuing to rise each year," said Sherwood Gorbach, the company's chief scientific officer, in a statement. "DIFICID is an important new first-line treatment option for patients who may be most at-risk of disease recurrence, for whom producing a sustained clinical response is critical."

The stock was last quoted at $13.66, up 5.2%, on volume of 175,000, according to Nasdaq.com. That move followed a 7% drop in the regular session to $12.98 on volume of 5.9 million, more than eight times the issue's trailing three-month daily average of around 670,000.

--Written by Michael Baron in New York.



>To contact the writer of this article, click here: Michael Baron.

>To submit a news tip, send an email to: tips@thestreet.com

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs